Does Thyroid Cause Fatty Liver? UK Guide

Does thyroid cause fatty liver? The answer is yes, thyroid dysfunction, particularly hypothyroidism, is a recognised contributing factor to fatty liver disease, known clinically as metabolic dysfunction-associated steatotic liver disease (MASLD) or non-alcoholic fatty liver disease (NAFLD). Thyroid hormones play a central role in regulating fat metabolism in the liver, and when levels fall, triglycerides can accumulate within liver tissue. This article explains the biological link, the symptoms to watch for, how UK doctors investigate both conditions, and when to seek medical advice.

Can a thyroid problem really cause fatty liver disease?

Yes, hypothyroidism is a recognised contributing factor to fatty liver disease, with research consistently showing higher prevalence of hepatic steatosis in people with low thyroid hormone levels, even at a subclinical stage.

Yes, thyroid dysfunction, particularly an underactive thyroid (hypothyroidism), is recognised as a contributing factor to the development of metabolic dysfunction-associated steatotic liver disease (MASLD), the term increasingly used in specialist practice alongside the more familiar non-alcoholic fatty liver disease (NAFLD), which remains the term used in many NHS patient-facing resources. Research, including systematic reviews and meta-analyses, has consistently shown that people with hypothyroidism have a higher prevalence of fatty liver compared with those who have normal thyroid function. The association is biologically plausible and is supported by the thyroid hormone's central role in regulating fat metabolism throughout the body.

Thyroid hormones, primarily triiodothyronine (T3), act directly on liver cells (hepatocytes) through specific nuclear receptors.^[7][5] When thyroid hormone levels are low, the liver's ability to break down and export fat is impaired, allowing triglycerides to accumulate within liver tissue. This process can occur even in people with subclinical hypothyroidism, where thyroid-stimulating hormone (TSH) is mildly elevated but free thyroxine (T4) remains within the normal range.^[3][4]

It is important to note that fatty liver disease is multifactorial. Obesity, type 2 diabetes, insulin resistance, and excess alcohol consumption are all well-established risk factors. Thyroid dysfunction is considered one contributing mechanism rather than a sole cause, and not everyone with hypothyroidism will develop fatty liver. However, the link is clinically meaningful enough that UK guidance, including NICE and British Society of Gastroenterology (BSG) recommendations, encourages clinicians to consider metabolic and endocrine causes, including thyroid status, when evaluating patients with unexplained liver enzyme abnormalities.

How an underactive thyroid leads to fat building up in the liver

Low T3 levels slow fatty acid oxidation, impair VLDL clearance, and promote insulin resistance, causing triglycerides to accumulate in liver cells via several reinforcing metabolic pathways.

An underactive thyroid causes fat to accumulate in the liver primarily by slowing the metabolic processes that normally keep lipid levels in balance. Thyroid hormones regulate several key pathways in lipid metabolism, including fatty acid oxidation (the burning of fat for energy), the synthesis and clearance of very low-density lipoprotein (VLDL) particles, and the activity of lipoprotein lipase, an enzyme that breaks down circulating fats. When T3 levels fall, all of these processes slow down, and triglycerides begin to build up both in the bloodstream and within liver cells.

Hypothyroidism also promotes insulin resistance, a state in which cells respond less effectively to insulin. Insulin resistance drives increased delivery of free fatty acids to the liver from adipose tissue, further loading the liver with fat it cannot efficiently process or export.^[6][4] This creates a cycle in which low thyroid hormone output, rising insulin resistance, and impaired fat oxidation reinforce one another.

Additionally, thyroid hormones appear to influence bile acid metabolism, which plays a role in liver health. Reduced bile acid synthesis in hypothyroidism may impair the liver's ability to clear cholesterol and fat-soluble compounds, though the precise contribution of this pathway in humans is still being investigated. In preclinical studies, thyroid hormone receptor agonists have been shown to reverse hepatic steatosis in animal models; this provides mechanistic evidence for the link but should not be taken to imply established clinical efficacy in humans. In humans, the liver expresses thyroid hormone receptor beta (THR-beta) at high levels, making it particularly sensitive to changes in circulating thyroid hormone concentrations.^[7][5] These combined mechanisms help explain why hypothyroidism, even at a subclinical level, is associated with an increased risk of fatty liver.

What are the signs that your liver and thyroid may both be affected?

Fatigue, weight gain, and sluggishness are shared symptoms of both conditions; fatty liver is often silent and discovered incidentally through elevated liver enzymes or ultrasound.

The symptoms of hypothyroidism and fatty liver disease overlap considerably, which can make it difficult to identify either condition without formal testing. Fatigue is among the most common complaints in both conditions, and many people attribute persistent tiredness to lifestyle factors rather than an underlying medical cause. Weight gain, difficulty losing weight despite dietary changes, and a general sense of sluggishness are also shared features.

Symptoms that may point more specifically to thyroid dysfunction include:

• Feeling cold more than usual, or cold intolerance

• Dry skin, hair thinning or hair loss

• Constipation

• Low mood or depression

• Puffiness around the face or eyes

• A slow heart rate

Fatty liver disease, in its early stages, is often entirely silent. Most people have no symptoms at all, and the condition is frequently discovered incidentally during an ultrasound scan or when routine blood tests reveal mildly elevated liver enzymes (alanine aminotransferase, ALT, or aspartate aminotransferase, AST). It is worth noting that liver enzyme levels can be within the normal range even when fatty liver is present, so a normal result does not exclude the diagnosis. In more advanced cases, some people report a dull ache or discomfort in the upper right abdomen, though this is not universal.

If fatty liver progresses to metabolic dysfunction-associated steatohepatitis (MASH), inflammation and liver cell damage become more significant, and over time this can lead to fibrosis or cirrhosis. At that stage, symptoms such as jaundice, abdominal swelling, or easy bruising may appear. Anyone experiencing a combination of thyroid-type symptoms alongside unexplained fatigue, weight changes, or abnormal liver blood tests should discuss both possibilities with their GP rather than assuming one diagnosis explains everything.

How do doctors in the UK test for thyroid-related fatty liver?

UK doctors use a serum TSH test for thyroid assessment and the FIB-4 index or NAFLD Fibrosis Score for liver fibrosis risk stratification, with abdominal ultrasound as the primary imaging tool.

UK doctors typically begin with blood tests when thyroid-related fatty liver is suspected, and the investigation of the two conditions often runs in parallel. For thyroid function, the standard first-line test is a serum TSH measurement, in line with NICE guideline NG145 on thyroid disease assessment and management.^[8] If TSH is abnormal, free T4 and sometimes free T3 are measured to clarify whether the thyroid is underactive, overactive, or functioning at a subclinical level. Thyroid peroxidase antibodies (TPO antibodies) may also be checked if autoimmune thyroid disease such as Hashimoto's thyroiditis is suspected.

For liver assessment, NICE guideline NG49 on NAFLD assessment and management recommends using the FIB-4 index or the NAFLD Fibrosis Score as first-line non-invasive tools to stratify the risk of advanced liver fibrosis in people at risk of MASLD or NAFLD.^[9][10] Where these scores indicate a higher risk of advanced fibrosis, the Enhanced Liver Fibrosis (ELF) blood test may be used as a second-line assessment, as described in NICE Diagnostics Guidance DG34.^[10][11] Liver enzyme levels (ALT, AST, gamma-glutamyl transferase) and a fasting lipid profile are also routinely checked, as dyslipidaemia is common in both hypothyroidism and fatty liver disease. Clinicians will also consider other common causes of abnormal liver blood tests, including alcohol intake, viral hepatitis, haemochromatosis, and certain medicines, before attributing findings to thyroid or metabolic causes, in line with BSG guidance on abnormal liver blood tests.

Ultrasound of the abdomen is the most widely used imaging tool for detecting hepatic steatosis in primary and secondary care. It is non-invasive, widely available on the NHS, and can identify fat infiltration of the liver, though it is less sensitive for mild steatosis. In cases where fibrosis is suspected, transient elastography (FibroScan) may be arranged, often via a hepatology or gastroenterology referral. Liver biopsy remains the gold standard for staging liver disease but is reserved for cases where non-invasive tests are inconclusive and the result would change clinical management. Access to ELF testing and transient elastography may vary depending on local Integrated Care Board (ICB) pathways, and a GP will coordinate investigations based on the individual's risk profile and clinical presentation.

Can treating your thyroid condition improve fatty liver?

Levothyroxine can improve lipid metabolism and liver enzyme levels in hypothyroid patients, but randomised trial evidence for direct liver benefit remains limited and it is not indicated for euthyroid individuals.

Treating hypothyroidism with levothyroxine, the standard NHS therapy for an underactive thyroid as recommended in NICE guideline NG145, can improve several of the metabolic abnormalities that contribute to fatty liver, though the evidence for direct liver benefit is still developing and largely observational.^[8] Levothyroxine restores circulating thyroid hormone levels, which in turn supports improved lipid metabolism, reduced insulin resistance, and better fatty acid oxidation within the liver. Observational studies have shown that TSH normalisation is associated with improvements in liver enzyme levels and, in some cases, reductions in hepatic fat content on imaging, though randomised controlled trial evidence remains limited.

It is important to note that levothyroxine is a treatment for hypothyroidism and is not indicated for weight loss in people with normal thyroid function. Using thyroid hormones for weight management in euthyroid individuals is not appropriate and carries risks.

Levothyroxine does not act selectively on the liver. It raises systemic T4 and T3 levels, which means the heart and bone are also exposed to higher thyroid hormone concentrations. Overtreatment, resulting in a suppressed TSH, carries its own risks, including atrial fibrillation and reduced bone density. For this reason, thyroid replacement is titrated carefully to keep TSH within the reference range. If you are taking levothyroxine and develop symptoms such as palpitations, tremor, or excessive sweating, discuss this with your GP or prescriber, as these may suggest over-replacement. Suspected side effects of any medicine, including levothyroxine, can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Researchers have investigated thyroid hormone receptor beta-selective agonists as a potential treatment for fatty liver, precisely because THR-beta is highly expressed in the liver and drives beneficial metabolic effects there without the cardiac and bone risks associated with systemic thyroid hormone excess. Resmetirom, a THR-beta agonist, has received regulatory approval in the United States for MASH, though it does not currently hold a UK marketing authorisation from the MHRA.^[14]

Alongside thyroid treatment, lifestyle modification remains central to managing fatty liver. NICE guideline NG49 and EASL guidance indicate that weight loss of around 7 to 10 per cent of body weight, achieved through dietary change and increased physical activity, is associated with meaningful reductions in hepatic steatosis and inflammation. Reducing alcohol intake is also an important component of liver health, regardless of thyroid status.

When should you speak to your GP about thyroid and liver symptoms?

See your GP if you have persistent fatigue, weight gain, or thyroid-type symptoms alongside risk factors for fatty liver; seek urgent care for jaundice, abdominal swelling, or signs of serious liver disease.

You should speak to your GP if you have persistent, unexplained fatigue, weight gain, or other symptoms consistent with hypothyroidism, particularly if you also have risk factors for fatty liver disease such as obesity, type 2 diabetes, or a family history of liver or thyroid conditions. A GP can arrange a TSH blood test and liver enzyme panel as a straightforward starting point, and these results will guide whether further investigation is needed.

Contact your GP promptly if you notice:

• Yellowing of the skin or whites of the eyes (jaundice)

• Persistent upper right abdominal discomfort

• Unexplained swelling of the abdomen

• Easy bruising or bleeding without obvious cause

• Significant and unexplained weight loss

• New confusion or unusual drowsiness, which can be a sign of serious liver disease

If you are already diagnosed with hypothyroidism and your thyroid replacement is well controlled but you continue to experience fatigue, weight difficulties, or abnormal liver blood tests, raise this with your GP. It is worth asking specifically whether your liver has been assessed, as the two conditions can coexist and each may need its own management plan. If you are on levothyroxine and develop symptoms that might suggest your dose needs reviewing, such as palpitations or feeling excessively warm, ask your GP to check your TSH.

For people seeking to understand their options for weight management alongside thyroid or liver concerns, an online consultation with a GPhC-registered pharmacy such as Bolt Pharmacy can provide prescriber review and pharmacist support, with any treatment only recommended where it is clinically appropriate following assessment.

If you develop sudden, severe abdominal pain, vomiting blood, or pass black or tarry stools, these are potential signs of a serious liver complication and you should call 999 or go to your nearest accident and emergency department immediately. For urgent but non-emergency concerns outside GP hours, NHS 111 can provide advice and direct you to the most appropriate service.

Scientific References

1. The reciprocal relationship between non-alcoholic fatty liver disease and hypothyroidism: A systematic review and meta-analysis of about 39 million individuals.
2. Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis.
3. Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction-associated steatotic liver disease: An observational study.
4. Effect of Hypothyroidism on Lipid Profile and Liver Enzymes: Implications In Non-Alcoholic Fatty Liver Disease.
5. New development for targeted therapy of non-alcoholic fatty liver disease with thyroid hormone receptor beta.
6. Thyroid hormone acts independently of the thyroid hormone receptor beta in hepatocytes to improve systemic insulin sensitivity.
7. Thyroid hormone receptor beta (THRβ1) is the major regulator of thyroid hormone action in human hepatocytes.
8. Thyroid disease: assessment and management. NICE guideline NG145.
9. Metabolic dysfunction-associated steatotic liver disease: assessment and management. NICE guideline NG49.
10. Assessment for advanced liver fibrosis in people with MASLD – NG49 chapter.
11. Liver disease quality standard QS152 – Quality statement 2: testing for advanced liver fibrosis.
12. Novel therapeutic targets for cholestatic and fatty liver disease.
13. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
14. First treatment against liver scarring caused by a type of fatty liver disease (resmetirom).

Frequently Asked Questions